Sino Biological Propure sets a new benchmark for endotoxin testing standards.
- Sino Biological launches an ultra-low endotoxin standard.
- New standard set at 0.05 EU/mg.
- Aim to enhance safety in biopharmaceutical production.
Sino Biological has introduced a groundbreaking ultra-low endotoxin standard of 0.05 EU/mg, aiming to improve safety in biopharmaceuticals. This new benchmark addresses the critical need for lower endotoxin levels to ensure product safety and effectiveness. The ultra-low endotoxin standard is expected to enhance the quality of various biopharmaceutical processes.
To achieve this reduced endotoxin threshold, Sino Biological has leveraged advanced purification technologies and stringent quality control measures. This innovation will likely support the production of safer therapeutic proteins and vaccines. By focusing on precision and quality, Sino Biological is addressing a significant challenge in the biopharmaceutical industry.
The development of this ultra-low endotoxin standard is essential as regulatory guidelines continue to tighten in the biopharmaceutical sector. Maintaining low endotoxin levels is crucial for patient safety, particularly for intravenous therapies. Sino Biological's commitment to this standard reflects their dedication to enhancing biopharmaceutical product quality.
